{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T12:13:43Z","timestamp":1792844023116,"version":"4.5.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T00:00:00Z","timestamp":1678838400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010962","name":"Institut des Sciences du Cerveau de Toulouse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010962","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","celltherapyjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.jcyt.2023.03.002","type":"journal-article","created":{"date-parts":[[2023,7,28]],"date-time":"2023-07-28T23:54:26Z","timestamp":1690588466000},"page":"920-929","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["International Society for Cell & Gene Therapy Position Paper: Key considerations to support evidence-based cell and gene therapies and oppose marketing of unproven products"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0993-6713","authenticated-orcid":false,"given":"Laertis","family":"Ikonomou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natividad","family":"Cuende","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0584-0389","authenticated-orcid":false,"given":"Miguel","family":"Forte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bambi J.","family":"Grilley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron D.","family":"Levine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Munsie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2975-807X","authenticated-orcid":false,"given":"John E.J.","family":"Rasko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7283-6809","authenticated-orcid":false,"given":"Leigh","family":"Turner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0204-0351","authenticated-orcid":false,"given":"Hamid R.","family":"Bidkhori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6297-7576","authenticated-orcid":false,"given":"Rachele","family":"Ciccocioppo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Grignon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alok","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9114-0735","authenticated-orcid":false,"given":"Patricia","family":"Zettler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce L.","family":"Levine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcyt.2023.03.002_bib0001","unstructured":"ISCT Presidential Task Force on the Use of Unproven Cellular Therapies, Reference Guide, 2015. https:\/\/www.isctglobal.org\/about\/isct-committees\/ecgt\/ptfreferenceguide. (Accessed March 3 2023)."},{"issue":"12","key":"10.1016\/j.jcyt.2023.03.002_bib0002","doi-asserted-by":"crossref","first-page":"2852","DOI":"10.1016\/j.stemcr.2021.10.007","article-title":"Weighing up the evidence used by direct-to-consumer stem cell businesses","volume":"16","author":"Cook","year":"2021","journal-title":"Stem Cell Rep"},{"issue":"6","key":"10.1016\/j.jcyt.2023.03.002_bib0003","doi-asserted-by":"crossref","first-page":"705","DOI":"10.2217\/rme-2017-0015","article-title":"ClinicalTrials.gov, stem cells and 'pay-to-participate' clinical studies","volume":"12","author":"Turner","year":"2017","journal-title":"Regen. Med."},{"issue":"8","key":"10.1016\/j.jcyt.2023.03.002_bib0004","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S2213-2600(18)30242-X","article-title":"Co-opting of ClinicalTrials.gov by patient-funded studies","volume":"6","author":"Wagner","year":"2018","journal-title":"Lancet Resp. Med."},{"issue":"6617","key":"10.1016\/j.jcyt.2023.03.002_bib0005","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1126\/science.abq8093","article-title":"Science, misinformation, and the role of education","volume":"378","author":"Osborne","year":"2022","journal-title":"Science"},{"issue":"1-2)i","key":"10.1016\/j.jcyt.2023.03.002_bib0006","article-title":"Cell banking for cell and gene therapy-regulatory, ethical, and scientific considerations","volume":"18","author":"Ikonomou","year":"2020","journal-title":"Bioprocess Int"},{"issue":"1","key":"10.1016\/j.jcyt.2023.03.002_bib0007","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jcyt.2015.11.004","article-title":"Part 1: defining unproven cellular therapies","volume":"18","author":"Srivastava","year":"2016","journal-title":"Cytotherapy"},{"issue":"7","key":"10.1016\/j.jcyt.2023.03.002_bib0008","doi-asserted-by":"crossref","first-page":"777","DOI":"10.2217\/rme-2017-0070","article-title":"Open for business: a comparative study of websites selling autologous stem cells in Australia and Japan","volume":"12","author":"Munsie","year":"2017","journal-title":"Regen. Med."},{"issue":"4","key":"10.1016\/j.jcyt.2023.03.002_bib0009","doi-asserted-by":"crossref","first-page":"375","DOI":"10.2217\/rme-2018-0007","article-title":"Selling stem cell 'treatments' as research: prospective customer perspectives from crowdfunding campaigns","volume":"13","author":"Snyder","year":"2018","journal-title":"Regen. Med."},{"issue":"397","key":"10.1016\/j.jcyt.2023.03.002_bib0010","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aag0426","article-title":"Marketing of unproven stem cell-based interventions: a call to action","volume":"9","author":"Sipp","year":"2017","journal-title":"Sci Transl Med"},{"issue":"5935","key":"10.1016\/j.jcyt.2023.03.002_bib0011","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1126\/science.1173712","article-title":"FDA regulation of stem cell-based products","volume":"324","author":"Fink","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.jcyt.2023.03.002_bib0012","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.addr.2014.12.001","article-title":"From bench to FDA to bedside: US regulatory trends for new stem cell therapies","volume":"82-83","author":"Knoepfler","year":"2015","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.jcyt.2023.03.002_bib0013","series-title":"Food & Drug Administration","year":"2021"},{"key":"10.1016\/j.jcyt.2023.03.002_bib0014","series-title":"PRIME: priority medicines","year":"2021"},{"key":"10.1016\/j.jcyt.2023.03.002_bib0015","series-title":"Strategy of SAKIGAKE","year":"2021"},{"key":"10.1016\/j.jcyt.2023.03.002_bib0016","series-title":"Approved cellular and gene therapy products","year":"2022"},{"issue":"11","key":"10.1016\/j.jcyt.2023.03.002_bib0017","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.jcyt.2018.09.010","article-title":"Cell, tissue and gene products with marketing authorization in 2018 worldwide","volume":"20","author":"Cuende","year":"2018","journal-title":"Cytotherapy"},{"issue":"12","key":"10.1016\/j.jcyt.2023.03.002_bib0018","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/j.jcyt.2014.08.007","article-title":"The puzzling situation of hospital exemption for advanced therapy medicinal products in Europe and stakeholders' concerns","volume":"16","author":"Cuende","year":"2014","journal-title":"Cytotherapy"},{"issue":"7","key":"10.1016\/j.jcyt.2023.03.002_bib0019","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.jcyt.2022.03.007","article-title":"Patient access to and ethical considerations of the application of the European Union hospital exemption rule for advanced therapy medicinal products","volume":"24","author":"Cuende","year":"2022","journal-title":"Cytotherapy"},{"issue":"10","key":"10.1016\/j.jcyt.2023.03.002_bib0020","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1056\/NEJMsr1715626","article-title":"Balancing safety and innovation for cell-based regenerative medicine","volume":"378","author":"Marks","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"6454","key":"10.1016\/j.jcyt.2023.03.002_bib0021","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1126\/science.aax6184","article-title":"Downgrading of regulation in regenerative medicine","volume":"365","author":"Sipp","year":"2019","journal-title":"Science"},{"issue":"9","key":"10.1016\/j.jcyt.2023.03.002_bib0022","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1002\/sctm.17-0282","article-title":"Concise review: a comprehensive analysis of reported adverse events in patients receiving unproven stem cell-based interventions","volume":"7","author":"Bauer","year":"2018","journal-title":"Stem Cells Transl. Med."},{"issue":"11","key":"10.1016\/j.jcyt.2023.03.002_bib0023","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1136\/medethics-2016-104046","article-title":"The deadly business of an unregulated global stem cell industry","volume":"43","author":"Lysaght","year":"2017","journal-title":"J. Med. Ethics"},{"key":"10.1016\/j.jcyt.2023.03.002_bib0024","series-title":"Harms Linked to Unapproved Stem Cell Interventions Highlight Need for Greater FDA Enforcement","author":"Richardson","year":"2021"},{"key":"10.1016\/j.jcyt.2023.03.002_bib0025","unstructured":"N. Ortolano, How do you separate scientifically sound stem cell therapies from scams?, 2020. https:\/\/www.statnews.com\/2020\/08\/18\/separate-scientific-scam-stem-cell\/. (Accessed March 3 2023)."},{"issue":"18","key":"10.1016\/j.jcyt.2023.03.002_bib0026","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1001\/jama.2018.3057","article-title":"Crowdfunding for unproven stem cell-based interventions","volume":"319","author":"Snyder","year":"2018","journal-title":"JAMA-J. Am. Med. Assoc."},{"key":"10.1016\/j.jcyt.2023.03.002_bib0027","series-title":"Committee for Advanced Therapies (CAT), EMA warns against using unproven cell-based therapies","year":"2020"},{"key":"10.1016\/j.jcyt.2023.03.002_bib0028","series-title":"FDA Warns About Stem Cell Therapies","year":"2019"},{"issue":"6","key":"10.1016\/j.jcyt.2023.03.002_bib0029","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/j.stemcr.2019.05.009","article-title":"How to peddle hope: an analysis of youtube patient testimonials of unproven stem cell treatments","volume":"12","author":"Hawke","year":"2019","journal-title":"Stem Cell Rep"},{"issue":"2","key":"10.1016\/j.jcyt.2023.03.002_bib0030","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1080\/105294199277860","article-title":"The International Conference on Harmonization Good Clinical Practice guideline","volume":"6","author":"Dixon","year":"1998","journal-title":"Qual Assur"},{"key":"10.1016\/j.jcyt.2023.03.002_bib0031","series-title":"Food & Drug Administration","year":"2020"},{"issue":"11","key":"10.1016\/j.jcyt.2023.03.002_bib0032","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1016\/j.stemcr.2021.09.005","article-title":"Ethical issues and public communication in the development of cell-based treatments for COVID-19: lessons from the pandemic","volume":"16","author":"Turner","year":"2021","journal-title":"Stem Cell Rep"},{"issue":"1","key":"10.1016\/j.jcyt.2023.03.002_bib0033","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/j.1748-720X.2012.00650.x","article-title":"The roles and responsibilities of physicians in patients' decisions about unproven stem cell therapies","volume":"40","author":"Levine","year":"2012","journal-title":"J. Law Med.Ethics"},{"issue":"2","key":"10.1016\/j.jcyt.2023.03.002_bib0034","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.jcyt.2017.10.002","article-title":"Medical societies, patient education initiatives, public debate and marketing of unproven stem cell interventions","volume":"20","author":"Weiss","year":"2018","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2023.03.002_bib0035","series-title":"Health Canada","year":"2019"},{"key":"10.1016\/j.jcyt.2023.03.002_bib0036","series-title":"Health Canada","year":"2020"},{"key":"10.1016\/j.jcyt.2023.03.002_bib0037","unstructured":"J.S. Eglovitch, WHO charts path to convergence on cell and gene therapies, 2022. https:\/\/www.raps.org\/news-and-articles\/news-articles\/2022\/1\/who-charts-path-to-convergence-on-cell-and-gene-th. (Accessed March 3 2023)."},{"issue":"6","key":"10.1016\/j.jcyt.2023.03.002_bib0038","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1016\/j.stemcr.2021.05.004","article-title":"Unproven stem cell interventions: a global public health problem requiring global deliberation","volume":"16","author":"Master","year":"2021","journal-title":"Stem Cell Rep"},{"issue":"16","key":"10.1016\/j.jcyt.2023.03.002_bib0039","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1001\/jama.2018.10264","article-title":"Medical crowdfunding for scientifically unsupported or potentially dangerous treatments","volume":"320","author":"Vox","year":"2018","journal-title":"JAMA-J. Am. Med. Assoc."},{"issue":"1","key":"10.1016\/j.jcyt.2023.03.002_bib0040","doi-asserted-by":"crossref","first-page":"14","DOI":"10.5966\/sctm.2016-0208","article-title":"The stem cell hard sell: report from a clinic's patient recruitment seminar","volume":"6","author":"Knoepfler","year":"2017","journal-title":"Stem Cells Transl. Med."},{"key":"10.1016\/j.jcyt.2023.03.002_bib0041","series-title":"Clinic pitches unproven treatments to desperate patients, with tips on raising the cash","author":"Wan","year":"2019"},{"issue":"3","key":"10.1016\/j.jcyt.2023.03.002_bib0042","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1001\/jama.2020.9375","article-title":"Identifying the risks of unproven regenerative medicine therapies","volume":"324","author":"Marks","year":"2020","journal-title":"JAMA-J. Am. Med. Assoc."},{"issue":"24","key":"10.1016\/j.jcyt.2023.03.002_bib0043","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1001\/jama.2019.5837","article-title":"Characteristics and scope of training of clinicians participating in the US direct-to-consumer marketplace for unproven stem cell interventions","volume":"321","author":"Fu","year":"2019","journal-title":"JAMA-J. Am. Med. Assoc."},{"key":"10.1016\/j.jcyt.2023.03.002_bib0044","doi-asserted-by":"crossref","DOI":"10.1186\/s12910-018-0273-6","article-title":"The involvement of Canadian physicians in promoting and providing unproven and unapproved stem cell interventions","volume":"19","author":"Ogbogu","year":"2018","journal-title":"BMC Med Ethics"},{"issue":"2","key":"10.1016\/j.jcyt.2023.03.002_bib0045","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.stem.2016.06.007","article-title":"Selling stem cells in the USA: assessing the direct-to-consumer industry","volume":"19","author":"Turner","year":"2016","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.jcyt.2023.03.002_bib0046","unstructured":"C. Kelly, \u2018FTC weighing trade rule on fake endorsements, including by \u2018patient ambassadors\u2019, 2020. https:\/\/pink.pharmaintelligence.informa.com\/PS147174\/FTC-Weighing-Trade-Rule-On-Fake-Endorsements-Including-By-Patient-Ambassadors. (Accessed March 3 2023)."},{"issue":"6287","key":"10.1016\/j.jcyt.2023.03.002_bib0047","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1126\/science.aaf4620","article-title":"Confronting stem cell hype","volume":"352","author":"Caulfield","year":"2016","journal-title":"Science"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324923000646?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324923000646?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,21]],"date-time":"2024-09-21T05:14:00Z","timestamp":1726895640000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324923000646"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":47,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S1465324923000646"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2023.03.002","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"International Society for Cell & Gene Therapy Position Paper: Key considerations to support evidence-based cell and gene therapies and oppose marketing of unproven products","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2023.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 International Society for Cell & Gene Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}